UBE2I and cancer: Knocking out UBC9 enhances sensitivity to anticancer drugs12,13, while small-molecule UBC9 inhibitors, such as 2-D08 and spectomycin B1, show some promise in ameliorating cancers in vitro and ex vivo14,15.